Related Experiment Video
Updated: Sep 19, 2025

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
Overlooked Trigger of Migraine: Clinical Significance of Small- and Medium-Shunt Patent Foramen Ovale
Jia-Ning Fan1, Ming-Fei Li1, Bei-Jian Zhang1
1National Clinical Research Center for Interventional Medicine, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Introduction:
Patent foramen ovale (PFO) is a prevalent congenital heart malformation closely linked with migraine. The effect of PFO size on migraine remains controversial.
Methods:
This study analyzed migraine patients who underwent PFO closure at our institution from January 2020 through December 2022. Based on transthoracic echocardiography findings, the patients were classified into two groups through two distinct classification approaches: method A - permanent shunt (PS) group or non-PS group, and method B - large shunt under Valsalva maneuver (LSVM) group or small-to-moderate shunt under Valsalva maneuver (SMSVM) group. Migraine improvement and adverse events after PFO closure were recorded.
Results:
A total of 201 migraine patients were included in this study, 110 (54.7%) had PS and 118 (58.7%) had LSVM. The PS and LSVM groups experienced less migraine burden (57.1 ± 64.5 vs. 88.5 ± 96.5 h, p = 0.035; 59.7 ± 67.3 vs. 88.9 ± 96.6 h, p = 0.039). The LSVM group had shorter headache episode durations (11.0 ± 8.2 vs. 14.4 ± 12.3 years, p = 0.045). The PS and LSVM groups showed less absolute reduction in migraine burden (33.8 ± 55.2 vs. 71.2 ± 84.9 h, p = 0.032; 33.9 ± 50.5 vs. 76.3 ± 92.8 h, p = 0.008). The LSVM group had a lower rate of alleviation (79.7% vs. 95.2%, p = 0.018). Medium-to-large residual shunt (MLRS) and SMSVM were independent predictors of migraine improvement, and a history of cryptogenic stroke (CS) was a predictor of migraine termination.
Conclusion:
SMSVM PFO in migraine patients has significant clinical implications and positive intervention outcomes. Both SMSVM and MLRS are associated with migraine relief, and a history of CS is a predictor of migraine termination.
Insights
Patent foramen ovale (PFO) closure improves migraine, especially with small-to-moderate shunts. This finding offers hope for migraine sufferers with PFO, highlighting shunt size as a key factor in treatment success.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Patent foramen ovale (PFO) is a common congenital heart defect linked to migraines.
- The relationship between PFO size and migraine severity is not fully understood.
Purpose of the Study:
- To investigate the impact of PFO size on migraine improvement after PFO closure.
- To identify predictors of migraine relief following PFO closure.
Main Methods:
- Retrospective analysis of 201 migraine patients who underwent PFO closure (Jan 2020-Dec 2022).
- Patients classified into groups based on PFO shunt size: permanent shunt (PS) vs. non-PS, and large shunt under Valsalva maneuver (LSVM) vs. small-to-moderate shunt under Valsalva maneuver (SMSVM).
- Migraine improvement and adverse events were recorded post-procedure.
Main Results:
- PFO closure reduced migraine burden in both PS and LSVM groups.
- The small-to-moderate shunt under Valsalva maneuver (SMSVM) group showed a lower rate of migraine alleviation (79.7% vs. 95.2%).
- Small-to-moderate shunt under Valsalva maneuver (SMSVM) and medium-to-large residual shunt (MLRS) predicted migraine improvement; cryptogenic stroke history predicted migraine termination.
Conclusions:
- Small-to-moderate shunt under Valsalva maneuver (SMSVM) PFO in migraine patients has positive intervention outcomes.
- Both SMSVM and MLRS are associated with migraine relief.
- A history of cryptogenic stroke is a predictor of migraine termination.
Related Concept Videos
Mitral Stenosis I: Introduction
Mitral Valve Prolapse I: Introduction
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Mitral Valve Prolapse III: Nursing Management
Mitral Valve Prolapse II: Assessment and Management

